Navigation Links
FDA's New Safety Controls for LABA-Containing Drugs Will Impact Prescribing of Single-Agent ICS and LABA/ICS Combination Therapies for the Treatment of Asthma
Date:8/24/2010

WALTHAM, Mass., Aug. 24 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that some surveyed physicians indicate that they will decrease their overall prescribing of long-acting beta2 agonists (LABA)/inhaled corticosteroids (ICS) combination therapies over the next 12 months for the treatment of asthma in response to the U.S. Food and Drug Administration's new safety controls for LABA-containing medications. Most notably, the FDA controls state that LABA/ICS combination medications should be reserved for patients who remain uncontrolled despite treatment with controller medications (e.g., single-agent ICS therapies).

According to the new report entitled Treatment Algorithms in Asthma, more than 40 percent of surveyed physicians report that they will decrease their prescribing of LABA/ICS combinations prior to attempting treatment with a single-agent ICS drug over the next 12 months.

While surveyed physicians indicate that the FDA controls for LABA-containing drugs will affect their decision to prescribe a LABA/ICS combination therapy prior to attempting treatment with a single-agent ICS, surveyed physicians also report that first-line prescribing of LABA/ICS combinations remains common. In particular, surveyed physicians are most likely to prescribe a LABA/ICS combination, such as GlaxoSmithKline's Advair or AstraZeneca's Symbicort, as a first-line maintenance therapy for newly diagnosed adult patients with moderate or severe persistent asthma.

"Some surveyed physicians say they will decrease their use of LABA/ICS combination medications for the treatment of asthma, a trend that may have positive implications for the single-agent ICS class of therapies," said Decision Resources Analyst Martin Quinn. "As a result, marketers of LABA/ICS combination medications and single-agent ICS therapies must focus not only on competitive dynamics within each class, but must also understand the increasing importance of interclass competitive dynamics."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from IMS LifeLink's Health Plans Claims database to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Chris Comfort781-296-2597ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of the ... to 2022" report to their offering. ... , , The global ultrasound ... is expected to grow at a CAGR of 5.5% during 2016-2022. Based ... during the forecast period, a CAGR of 8.8% in the global market. ...
(Date:12/2/2016)... Quantum Radiology,s Mobile Breast Center (QR MBC) brings cutting-edge ... at the workplace, thereby maximizing convenience and compliance.  QR ... and SunTrust Bank, and community health groups to provide ... "I think it,s a great service for ... a mammogram without taking a large amount of time ...
(Date:12/2/2016)... 2, 2016 In the first ever attempt ... those derived from C. sativa, the Hebrew University in ... Napoli Federico II , the Universita` del Piemonte Orientale ... critical, integrated and unified inventory of phytocannabinoids of different ... on the remarkable chemical and structural diversity of phytocannabinoids. ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... CloudLIMS.com, a class-leading ... LIMS, CloudLIMS Lite. CloudLIMS Lite helps biobanks, clinical, research and testing laboratories keep ... disposal. The new version is a faster and a more efficient product, allowing ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... diagnostic imaging systems and the first company to offer robotic imaging to ... at their tradeshow booth # 941 for the American Association of Equine Practitioners ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ... and night. No other wearable health technology on the market can deliver all that ... poeple more meaningful insights about their health than the usual heart rate and steps ...
(Date:12/2/2016)... ... 2016 , ... "Pro3rd Accents Volume 2 is a set of 30 accented ... with just a few clicks of the mouse," said Christina Austin - CEO of ... Choose from various styles with accented animations, rigid boxes, simplistic lines, and more. In ...
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
Breaking Medicine News(10 mins):